Department of Translational and Regenerative Medicine, PGIMER, Chandigarh, 160012, India.
Stem Cell Rev Rep. 2024 Apr;20(3):738-754. doi: 10.1007/s12015-024-10684-9. Epub 2024 Feb 9.
Kidney Disease (KD), has a high global prevalence and accounts for one of the most prominent causes of morbidity and mortality in the twenty-first century. Despite the advances in our understanding of its pathophysiology, the only available therapy options are dialysis and kidney transplantation. Mesenchymal stem cells (MSCs) have proven to be a viable choice for KD therapy due to their antiapoptotic, immunomodulatory, antioxidative, and pro-angiogenic activities. However, the low engraftment, low survival rate, diminished paracrine ability, and delayed delivery of MSCs are the major causes of the low clinical efficacy. A number of preconditioning regimens are being tested to increase the therapeutic capabilities of MSCs. In this review, we highlight the various strategies to prime MSCs and their protective effects in kidney diseases.
肾脏疾病（KD）在全球范围内具有较高的患病率，是 21 世纪发病率和死亡率的主要原因之一。尽管我们对其病理生理学的认识有所提高，但唯一可用的治疗选择仍然是透析和肾移植。间充质干细胞（MSCs）由于其抗凋亡、免疫调节、抗氧化和促血管生成作用，已被证明是 KD 治疗的可行选择。然而，MSC 的低植入率、低存活率、旁分泌能力降低和延迟递送是其临床疗效低的主要原因。目前正在测试多种预处理方案以提高 MSC 的治疗能力。在这篇综述中，我们强调了各种预处理 MSC 的策略及其在肾脏疾病中的保护作用。
